Balyasny Asset Management
MDGL icon

Balyasny Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Balyasny Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,000
Closed -$582K – 3258
2025
Q4 		$582K Sell
1,000
-1,100
-52% -$562K ﹤0.01% 2459
2025
Q3 		$963K Buy
+2,100
New +$783K ﹤0.01% 2130
2019
Q1 		– Sell
-20,000
Closed -$2.25M – 1538
2018
Q4 		$2.25M Buy
+20,000
New +$3.1M 0.02% 691

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Balyasny Asset Management's MDGL Position: Q4 2025 in Review

Balyasny Asset Management sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2025, closing a stake of 82,401 shares — an estimated $42.1M sold.

Balyasny Asset Management first reported a position in MDGL in Q4 2022 and held it in 7 quarters. The position peaked at $37.8M in Q3 2025. 387 funds tracked by Wall St. Rank hold MDGL as of Q4 2025.

  • Balyasny Asset Management reported no remaining Madrigal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Balyasny Asset Management sold 82,401 Madrigal Pharmaceuticals shares in Q4 2025, an estimated $42.1M.
  • Balyasny Asset Management first reported a position in Madrigal Pharmaceuticals in Q4 2022 and held it in 7 quarters.
  • Balyasny Asset Management's Madrigal Pharmaceuticals position peaked at $37.8M in Q3 2025.
  • 387 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2025.

Based on Balyasny Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.